Fraudulently Doctored Images and “Suspect Data” in Many Leading Cancer Research Papers

Charles Piller in his Doctored paints a damning picture of doctored images and suspect data rampant in the leading scientific literature on Alzheimer’s disease. Not only were leading scientists guilty of fraud, but the key institutions of scientific research (journals, universities, and government grant-making agencies) failing their oversight duty, and when outsiders stepped in to provide oversight, delayed and minimized their responses. Practicing and turning a blind eye to fraud matters, since Alzheimer’s patients are depending on this research. And researchers who do not commit fraud suffer because they appear to have worse research records than those compiled by the fraudsters. So the honest get worse academic appointments and fewer grants.

After reading Doctored I was depressed, but I at least hoped that this pathology was limited to this one (albeit an important one) area of medical research. But in the article quoted below, evidence is presented that there is substantial similar doctored images and suspect data in the field of cancer research.

A side issue in the quoted article is worth highlighting. In the absence of credible oversight from the institutions tasked with oversight, oversight is being done by competent volunteers, with the aid of A.I. These volunteers do not receive compensation for their work, and in fact are probably pay a price for it, since they alienate powerful scientists and scientific institutions. But if science is a search for truth, and truth matters for cures, they are doing a service to us all, and especially to those who suffer from major diseases such as Alsheimer’s and cancer.

On the connection with the Doctored book, it is worth noting that the article quotes Dr. Matthew Schrag, who is the most important source in Doctored. The article also quoted Elisabeth Bik, who does not have an MD like Schrag but has a PhD in microbiology, and who is another important source in Doctored.

(p. A1) The stomach cancer study was shot through with suspicious data. Identical constellations of cells were said to depict separate experiments on wholly different biological lineages. Photos of tumor-stricken mice, used to show that a drug reduced cancer growth, had been featured in two previous papers describing other treatments.

Problems with the study were severe enough that its publisher, after finding that the paper violated ethics guidelines, formally withdrew it within a few months of its publication in 2021. The study was then wiped from the internet, leaving behind a barren web page that said nothing about the reasons for its removal.

As it turned out, the flawed study was part of a pattern. Since 2008, two of its authors — Dr. Sam S. Yoon, chief of a cancer surgery division at Columbia University’s medical center, and a more junior cancer biologist — have collaborated with a rotating cast of researchers on a combined 26 articles that a British scientific sleuth has publicly flagged for containing suspect data. A medical journal retracted one of them this month after inquiries from The New York Times.

Memorial Sloan Kettering Cancer Center, where Dr. Yoon worked when much of the research was done, is now investigating the studies. Columbia’s medical center declined to comment on specific allegations, saying only that it reviews “any concerns about scientific integrity brought to our attention.”

Dr. Yoon, who has said his research could lead to better cancer treatments, did not answer repeated questions. Attempts to speak to the other researcher, Changhwan Yoon, an associate research scientist at Columbia, were also unsuccessful.

The allegations were aired in recent months in online comments on a science forum and in a blog post by Sholto David, an independent molecular biologist. He has ferreted out problems in a raft of high-profile cancer research, including dozens of papers at a Harvard cancer center that were subsequently referred for retractions or corrections.

From his flat in Wales, Dr. David pores over published images of cells, tumors and mice in his spare (p. A17) time and then reports slip-ups, trying to close the gap between people’s regard for academic research and the sometimes shoddier realities of the profession.

. . .

Armed with A.I.-powered detection tools, scientists and bloggers have recently exposed a growing body of such questionable research, like the faulty papers at Harvard’s Dana-Farber Cancer Institute and studies by Stanford’s president that led to his resignation last year.

But those high-profile cases were merely the tip of the iceberg, experts said. A deeper pool of unreliable research has gone unaddressed for years, shielded in part by powerful scientific publishers driven to put out huge volumes of studies while avoiding the reputational damage of retracting them publicly.

The quiet removal of the 2021 stomach cancer study from Dr. Yoon’s lab, a copy of which was reviewed by The Times, illustrates how that system of scientific publishing has helped enable faulty research, experts said. In some cases, critical medical fields have remained seeded with erroneous studies.

“The journals do the bare minimum,” said Elisabeth Bik, a microbiologist and image expert who described Dr. Yoon’s papers as showing a worrisome pattern of copied or doctored data. “There’s no oversight.”

. . .

Dr. Yoon, a stomach cancer specialist and a proponent of robotic surgery, kept climbing the academic ranks, bringing his junior researcher along with him. In September 2021, around the time the study was published, he joined Columbia, which celebrated his prolific research output in a news release. His work was financed in part by half a million dollars in federal research money that year, adding to a career haul of nearly $5 million in federal funds.

. . .

The researchers’ suspicious publications stretch back 16 years. Over time, relatively minor image copies in papers by Dr. Yoon gave way to more serious discrepancies in studies he collaborated on with Changhwan Yoon, Dr. David said. The pair, who are not related, began publishing articles together around 2013.

But neither their employers nor their publishers seemed to start investigating their work until this past fall, when Dr. David published his initial findings on For Better Science, a blog, and notified Memorial Sloan Kettering, Columbia and the journals. Memorial Sloan Kettering said it began its investigation then.

. . .

A proliferation of medical journals, they said, has helped fuel demand for ever more research articles. But those same journals, many of them operated by multibillion-dollar publishing companies, often respond slowly or do nothing at all once one of those articles is shown to contain copied data. Journals retract papers at a fraction of the rate at which they publish ones with problems.

. . .

“There are examples in this set that raise pretty serious red flags for the possibility of misconduct,” said Dr. Matthew Schrag, a Vanderbilt University neurologist who commented as part of his outside work on research integrity.

. . .

Experts said the handling of the article was symptomatic of a tendency on the part of scientific publishers to obscure reports of lapses.

“This is typical, sweeping-things-under-the-rug kind of nonsense,” said Dr. Ivan Oransky, co-founder of Retraction Watch, which keeps a database of 47,000-plus retracted papers. “This is not good for the scientific record, to put it mildly.”

For the full story, see:

Benjamin Mueller. “Cancer Doctor Is in Spotlight Over Bad Data.” The New York Times. (Fri., February 16, 2024): A1 & A17.

(Note: ellipses added.)

(Note: the online version has the date Feb. 15, 2024 [sic], and has the title “A Columbia Surgeon’s Study Was Pulled. He Kept Publishing Flawed Data.”)

Piller’s book mentioned in my initial comments is:

Piller, Charles. Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s. New York: Atria/One Signal Publishers, 2025.

Health Freedom Is a Right AND Can Yield More and Faster Therapies

The headline of the article on the front page of the NYT says “No Evidence for Healing Powers,” and goes on to slam unsophisticated right-wingers as irresponsibly pushing ivermectin as a therapy for cancer. In the article the NYT publishes a ludicrous picture from a right-winger’s Facebook page where he has spread veterinary ivermectin cream on his tongue and says “tastes like dead cancer.”

But this is unfair and tendentious caricature. A friend recently sent me an Instagram post by a chiropractor suffering from glioblastoma who has taken ivermectin and mebendazole. He briefly sketches the hypothesized mechanisms for activity of the two drugs, consistent with research published in scientific papers.

Glioblastoma is a serious, often fatal, brain cancer. He had surgery, but knows that surgery often does not cure, so he threw a Hail Mary and took ivermectin and mebendazole. These drugs have long track-records for safety, having been tested and approved for other uses. Doctors can, and have, prescribed drugs for off-label uses for decades.

Decades ago minoxidil was approved as an blood pressure medicine. I asked my then-doctor to prescribe it for me for its rumored effects as a hair loss cure. He did, so I crushed the tablets and somehow applied them to my scalp, which proceeded to itch, but not grow hair. It was a low-risk, modest-chance-of-success experiment. I think I had a right to try it, and that no government or expert had a right to forbid it. (Eventually minoxidil was approved for hair loss and branded Rogaine–which still didn’t work for me.)

In a free country adults should have wide latitude to make decisions about what risks they take; to scuba dive, to drive NASCAR, to go into space, and yes to take ivermectin and mebendazole. And the ludicrous right-winger? Hey, maybe even he has rights.

The NYT headline says there is “no evidence” for ivermectin. Below I cite a survey article that identifies 24 articles published in scientific journals identifying mechanisms by which ivermectin may be effective against cancer. There’s plenty of evidence, just not from randomized double-blind clinical trials (RCTs). But as long-time readers of this blog may remember, I have posted many entries giving useful actionable evidence that takes forms other than RCTs.

“No evidence”? Maybe the NYT was seeking plausible deniability by running its article on April 1st.

Oh, and by the way, allowing health freedom might sometimes result in better and faster therapies. I am currently reading Rethinking Diabetes by Gary Taubes. He tells the story (pp. 346-356) of Richard K. Bernstein, an engineer with Type 1 diabetes who was suffering from various serious ailments from his diabetes, in spite of the doctors saying it was being well-controlled by insulin. In his 40s, he was only expected to live another 10 years. Well he bought a new device that was not supposed to be bought by patients. The medical profession thought patients could not handle the information. (His wife was an MD, so he ‘bought’ it by asking her to buy it for him.) The device allowed him to get frequent readings of his blood sugar, and thereby to better control it, ultimately through changes in diet. When he tried to share what he had learned, he had trouble finding anyone who would take him seriously, so in his 40s he enrolled in medical school, and started publishing papers and books describing his results.

Richard K. Bernstein died on April 15, 2025 at age 90.

[Below are some relevant quotations from a NYT companion piece to the front-page article. The companion piece provides only slightly less tendentious background information on ivermectin.]

(p. A21) . . . there is not evidence to support people taking ivermectin to treat cancer.

. . .

Scientists do not dispute that ivermectin is powerfully effective — against parasites. The drug was such a breakthrough in the fight against tropical parasitic diseases that two scientists who studied it won the Nobel Prize in 2015.

The Food and Drug Administration has approved ivermectin tablets to treat certain parasitic infections, and the agency has authorized ivermectin lotions to kill lice and creams to help with rosacea. Veterinarians also use the drug to prevent and treat parasitic diseases in animals.

. . .

Studies in human cells suggest that the drug may kill certain types of cancer cells in a way that triggers the immune system, said Dr. Peter P. Lee, chair of the department of immuno-oncology at Beckman Research Institute of City of Hope in Duarte, Calif. In mouse studies, Dr. Lee has seen that the drug, on its own, does not shrink breast tumors. But it’s possible that the drug may have benefits for breast cancer when used alongside existing cancer immunotherapy, he said. Researchers are studying a combination of ivermectin and an investigational cancer drug in people with breast cancer.

While some inaccurate social media posts claim that ivermectin can treat cancer because tumors themselves are parasitic, the promise of ivermectin for cancer has nothing to do with its anti-parasitic effect, Dr. Lee said. Rather, it seems that the drug may be able to modulate a signal involved with cancer growth.

But doctors still need larger, randomized clinical trials to better understand whether ivermectin could treat cancer. Just because a drug seems to work in animals doesn’t mean those results will translate into real-world outcomes, Dr. Johnson noted. There are “hundreds of medications that look to be promising in a preclinical setting” every year, he said, adding, “The vast majority of those will never be shown to be effective in humans.”

. . .

Doctors generally view ivermectin as safe at the doses prescribed to treat parasitic infections.

For the full story, see:

Dani Blum. “What Ivermectin Can and Can’t Do, and What the Dangers Are.” The New York Times (Tues., April 1, 2025): A21.

(Note: ellipses added.)

(Note: the online version has the date March 31, 2025, and has the title “What Ivermectin Can (and Can’t) Do.” In the first quoted sentence, the print version says “no evidence” and the online version says “not evidence.”)

The Blum article that I just quoted and cited, is a secondary companion article to a longer front-page article, also on ivermectin:

Richard Fausset. “No Evidence for Healing Powers, but ‘Tastes Like Dead Cancer’.” The New York Times (Tues., April 1, 2025): A1 & A21.

(Note: the online version has the date March 31, 2025, and has the title “Why the Right Still Embraces Ivermectin.”)

The paper cited below reviewed the published scientific literature as of 2020 on the mechanisms through which ivermectin could have anti-cancer effects, finding 24 articles documenting one or more mechanisms.

Tang, Mingyang, Xiaodong Hu, Yi Wang, Xin Yao, Wei Zhang, Chenying Yu, Fuying Cheng, Jiangyan Li, and Qiang Fang. “Ivermectin, a Potential Anticancer Drug Derived from an Antiparasitic Drug.” Pharmacological Research 163 (Jan. 2021): 105207.

Tang and co-authors are optimistic in their summary section quoted below. [In this quote IVM is “ivermectin” and MDR is “multidrug resistance”.]

. . ., the broad-spectrum antiparasitic drug IVM, which is widely used in the field of parasitic control, has many advantages that suggest that it is worth developing as a potential new anticancer drug. IVM selectively inhibits the proliferation of tumors at a dose that is not toxic to normal cells and can reverse the MDR of tumors. Importantly, IVM is an established drug used for the treatment of parasitic diseases such as river blindness and elephantiasis. It has been widely used in humans for many years, and its various pharmacological properties, including long- and short-term toxicological effects and drug metabolism characteristics are very clear. (Tang et al. Jan. 2021, pp. 7-8)

The paper cited below reviewed the published scientific literature as of 2019 on the effect of mebendazole on cancer, and found 26 in vitro studies showing anti-cancer biological effects, 14 in vivo studies showing anti-tumor effects, and six Phase 1 or Phase 2 clinical trials listed in ClinicalTrials.gov.

Guerini, Andrea Emanuele, Luca Triggiani, Marta Maddalo, Marco Lorenzo Bonù, Francesco Frassine, Anna Baiguini, Alessandro Alghisi, Davide Tomasini, Paolo Borghetti, Nadia Pasinetti, Roberto Bresciani, Stefano Maria Magrini, and Michela Buglione. “Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature.” Cancers 11, no. 9 (Aug. 2019): article #1284.

Gary Taubes’s book, praised by Marty Makary and Siddhartha Mukherjee, and mentioned by me near the end of my commentary, is:

Taubes, Gary. Rethinking Diabetes: What Science Reveals About Diet, Insulin, and Successful Treatments. New York: Knopf, 2024.

[I thank Ivette Locay for sending me a link useful for my commentary.]

Ramaswamy Avowed That the F.D.A. “Erects Unnecessary Barriers to Innovation”

The New York Times article quoted below worried that if Vivek Ramaswamy succeeded in “slashing regulation” of drugs, his own drug development firm would have benefitted. Maybe so, but that misses the main point–all the rest of us also would have benefitted by medical entrepreneurs being allowed to create more and quicker cures. Presumably The New York Times was relieved when Ramaswamy resigned from DOGE, but I was discouraged.

I was in favor of Elon Musk’s push to reduce the number of federal employees. But I was even more in favor of Vivek Ramaswamy’s push to deregulate innovative entrepreneurs.

[By the way, isn’t it predictable that The New York Times delights in highlighting Roivant’s one failure, but gives only passing scant mention to its six successes?]

(p. A10) Vivek Ramaswamy is the less famous and less wealthy half of the duo of billionaires that President-elect Donald J. Trump has designated to slash government costs.

. . .

At 39, he is one of the world’s youngest billionaires, having made his fortune in the pharmaceutical industry.  . . .

Mr. Ramaswamy, who owns a stake currently valued at nearly $600 million in a biotechnology company he started, has called for changes at the Food and Drug Administration that would speed up drug approvals.

. . .

Since being named to jointly lead DOGE, Mr. Ramaswamy had until recently been posting on Mr. Musk’s social media site X, hinting about where he may look to make changes in the government.

He called for slashing regulation, not just cutting government spending. He pointed to federal workers focused on diversity as potential targets for “mass firings.”

And he has been taking aim at the F.D.A. “My #1 issue with FDA is that it erects unnecessary barriers to innovation,” he wrote on X. He criticized the agency’s general requirement that drugmakers conduct two successful major studies to win approval rather than one.

Mr. Ramaswamy founded his biotechnology company, Roivant Sciences, in 2014, betting that he could find hidden gems whose potential had been overlooked by large drugmakers. The idea was to hunt for experimental medications languishing within large pharmaceutical companies, buy them for cheap and spin out a web of subsidiaries to bring them to market.

The venture is best known for a spectacular failure.

In 2015, Mr. Ramaswamy whipped up hype and investment around one of his finds, a potential treatment for Alzheimer’s disease being developed by one of his subsidiaries, Axovant. Two years later, a clinical trial showed that it did not work, erasing more than $1.3 billion in Axovant’s stock value in a single day.

Mr. Ramaswamy personally lost money on paper on the failure, but thanks to the savvy way he had structured his web of companies he and Roivant weathered the storm. Six products have won F.D.A. approval, and today Roivant has a market valuation of $8 billion.

Mr. Ramaswamy sold some of his Roivant stock to take a large payout in 2020, reporting nearly $175 million in capital gains on his tax return that year. But he is still one of the company’s largest shareholders.

If Mr. Ramaswamy recommends changes that speed up drug approvals through DOGE, that could be good news for Roivant, which is developing drugs that might come up for approval during Mr. Trump’s second term. The faster it can get medicines onto the market, the more valuable the company — and Mr. Ramaswamy’s stake in it — stands to become.

For the full story see:

Rebecca Robbins, Maureen Farrell and Jonathan Weisman. “From Ramaswamy’s High-Profile Perch, a Web of Potential Conflicts.” The New York Times (Thursday, January 16, 2025): A10.

(Note: ellipses added.)

(Note: the online version of the story has the date Jan. 15, 2025, and has the title “Ramaswamy Has a High-Profile Perch and a Raft of Potential Conflicts.” At one point this entry was posted on March 30. I had not noted that another entry had been posted for March 30, so for consistency I moved this entry to April 23.)

New York Times Cancels Pamela Paul–the Gutsy, Honest Defender of the Unfairly Canceled

The New York Times always leaned left, but would often present alternative viewpoints. In recent years the bias was strong and strident. But sometimes in the last several months I thought that I saw the dawning of a few more glimmers of fairness. A few of those glimmers came a couple of years ago when I first noticed the commentaries of Pamela Paul. She occasionally told stories that were true but were not politically correct. She occasionally defended those who had been unfairly cancelled. Sometimes I would finish one of her columns and feel hope in my heart for our society and even for The New York Times. (I ran blog entries highlighting Pamela Paul commentaries here, here, here, here, here, and here.)

But today I was catching up on some unread papers and read her “Farewell Column.” I immediately Googled her name and learned that she had been fired, canceled, by The New York Times. What a sad, sorry day. I hope she prospers somewhere else.

I will continue to subscribe to The New York Times for now. I still find enough value in niches as yet unruined by the Times‘s cancel culture: the Tuesday “Science Times” section, sometimes obituaries, sometimes business stories, and sometimes international stories (especially on China).

Here is little of what she wrote in “Farewell”:

(p. A23) I knew my positions, fundamentally liberal but often at odds with what had become illiberal progressive dogma, would ruffle feathers. But as I explained, “I want to write about that vast center/liberal space and to address what people really think and believe but are often too afraid to say.”

. . .

I did not want my positions to be unduly guided by what others might think, be they friends or strangers, office colleagues or online trolls, activist organizations or institutional powers. And the lure of affirmation can be just as potent as the fear of attack.

. . .

. . . the reporting I’m most proud of is when I used my voice to stand up for people whose lives or work had come under attack, whether they were public figures or were dragged into the public eye because they’d dared to speak or act in ways that unjustly elicited professional or social condemnation: A popular novelist ostracized for alleged “cultural appropriation.” A physician assistant who was excoriated on social media for standing up to bullies. A Palestinian writer whose appearance at a prominent book fair was canceled. An early beneficiary of affirmative action who dared to explore its unintended consequences. Vulnerable gay teenagers who described being misled by a politicized medical establishment into dubious gender transition treatments. A public university president who was driven away by a campus besieged with political division. Social work students and faculty members undermined by a school that had betrayed its own principles. A public health expert who risked opprobrium from his peers by calling out his profession on groupthink.

All found themselves at odds with the people or communities that had once supported them, a disorienting place to be, especially in these polarized times.

Pamela Paul’s last commentary for The New York Times is:

Pamela Paul. “My Farewell Column.” The New York Times (Fri., April 4, 2025): A23.

(Note: ellipses added.)

(Note: the online version of the commentary has the date April 3, and has the same title as the print version.)

How a Progressive, About to Pretend to Be a Conservative, Dropped the Pretense

How does a person totally change from one viewpoint to a totally different viewpoint? A thought-provoking case study was presented in a full page article in The New York Times.

In 2020 Xaviaer DuRousseau was a black progressive scheduled to appear on “The Circle,” a Netflix reality contest show in which his role was to sometimes attempt to fool the other participants into thinking that he was a conservative. To prepare himself to effectively deceive, he started studying conservative popular media, including the video clips of PragerU and of black social media pundit Candace Owens.

As he worked through the arguments he planned to make as a faux conservative on “The Circle,” he gradually realized that he was more and more agreeing with them, and eventually could no longer honestly be a “faux” conservative. So DuRousseau dropped the “faux” and resigned from the Netflix show.

Now Xaviaer DuRousseau is a full-fledged conservative, himself making popular videos for PragerU.

A surprising story in a surprising venue.

The full-page article in The New York Times is:

Kellen Browning and Mark Abramson. “How a Black Progressive Became a Conservative Star.” The New York Times (Thurs., April 10, 2025): A12.

(Note: the online version of the article was updated April 3, 2025, and has the title “How a Black Progressive Transformed Into a Conservative Star.”)

Rex Murphy Saw We Are Governed by People Who Look Down on Us

(p. B12) Rex Murphy, a Canadian newspaper, radio and television commentator who delighted his country’s conservatives with sharp attacks on environmentalists, liberal politicians and what he called their “woke politics,” died on May 9 [2024] in Toronto. He was 77.

His death, from cancer, was announced on the front page of The National Post, the widely read daily newspaper for which he wrote a column, one of several he had over the years in Canadian papers, including The Globe and Mail in Toronto. His editor at The National Post, Kevin Libin, said Mr. Murphy died in a hospital.

. . .

Mr. Murphy’s sharp political turn to the right — from commenting for centrist outlets like the CBC and The Globe and Mail, where he had a regular column until 2010, to the right-wing views he espoused at The National Post — had its roots in his own working-class background, in the view of those who knew him.

. . .

He regularly took on what he deemed the sins of “woke” politics and “wokeism.” In a February 2023 column, he wrote: “I have finally fixed upon the definition of progressivism. It means the dismissal of everything that counts, unconcern with what makes life hard for most, and a scorn for the realities of day to day; instead shepherding to very particular political interest groups.”

In his final days there were diatribes against critics of Israel during its war with Hamas and against the liberalism of Prime Minister Justin Trudeau.

. . .

Mr. Murphy was animated, Mr. Libin said, by “the sense that we were being governed by people who looked down on us.”

. . .

Throughout his career, Mr. Murphy set great store by verbal expression. His fans and his critics agreed that his distinctive, sometimes high-flown use of English was what set him apart from his country’s other journalists. Profiles noted that he was as devoted to the works of John Milton as he was to “The Simpsons.”

For the full obituary see:

Adam Nossiter. “Rex Murphy, 77, a Pundit on the Right in Canada.” The New York Times (Friday, May 24, 2024): B12.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the obituary was updated May 23, 2024, and has the title “Rex Murphy, a Dominant Pundit on the Right in Canada, Dies at 77.”)

As Temps Rise, Trees Adapt to Global Warming by Slowing Their Increasing Release of Carbon Dioxide

The late great physicist Freeman Dyson was courageously skeptical of global warming based on forces that move Earth back toward equilibrium when initially nudged away. The story quoted below provides evidence consistent with Dyson’s narrative.

(p. D2) The bend-don’t-break adaptability of trees extends to handling climate change, according to a new study that says forests may be able to deal with hotter temperatures and contribute less carbon dioxide to the atmosphere than scientists previously thought.

In addition to taking in carbon dioxide during photosynthesis, plants also release it through a process called respiration. Globally, plant respiration contributes six times as much carbon dioxide to the atmosphere as fossil fuel emissions, much of which is reabsorbed by plants, the oceans and other elements of nature. Until now, most scientists have thought that a warming planet would cause plants to release more carbon dioxide into the atmosphere, which in turn would cause more warming.

But in a study published Wednesday [March 16, 2016 [sic]] in Nature, scientists showed that plants were able to adapt their respiration to increases in temperature over long periods of time, releasing only 5 percent more carbon dioxide than they did under normal conditions.

Based on measurements of short-term temperature responses in this study and others, the scientists expected that the plants would increase their respiration by nearly five times that much.

At two forest-research sites in Minnesota, scientists tested how the respiration rates of 10 different species of trees — from boreal and temperate forests — were affected by increases in temperature over a period of three to five years, using heating cables to warm some of the trees.

The trees were monitored in two conditions: ambient, and about 6 degrees warmer than that.

To demonstrate how the plants adapted to long-term temperature increases, the scientists compared three things: how much carbon dioxide the trees released in ambient conditions; how much the trees released in the warmer conditions; and how much carbon dioxide the trees released when they were exposed to the warmer temperature for a short period of time (minutes or hours).

When the scientists compared the results, they found that the trees that were acclimated to the warmer temperatures increased their carbon dioxide release by a much smaller amount than the trees that were only exposed to a short-term temperature increase of the same magnitude.

Boreal and temperate forests account for a third of the world’s forest areas. If they are able to adapt respiration rates as this study suggests, the planet will breathe easier.

The source of the story is:

Tatiana Schlossberg. “Energy Appetite in U.S. Endangers Goals on Climate.” The New York Times (Tuesday, March 22, 2016 [sic]): D2.

(Note: bracketed date added.)

(Note: the online version of the story was updated March 16, 2016 [sic], and has the title “Trees Deal With Climate Change Better Than Expected.” The last two sentences quoted above differ in a non-trivial way in the print and the online versions. Above I choose to quote the less politically correct print version. The wimpish politically correct online version is: “Boreal and temperate forests account for a third of the world’s forest areas, and if they adapt their respiration rates in the way this study suggests, the forests, the planet’s lungs, can breathe easy.”)

The Nature article mentioned above is:

Reich, Peter B., Kerrie M. Sendall, Artur Stefanski, Xiaorong Wei, Roy L. Rich, and Rebecca A. Montgomery. “Boreal and Temperate Trees Show Strong Acclimation of Respiration to Warming.” Nature 531, no. 7596 (March 16, 2016): 633-36.

Mirsky Saw Communist “Soldiers Shoot Parents,” Doctors and Nurses Trying to Help Students in Tiananmen Square

(p. A21) Dr. Mirsky was a professor of Chinese language and history at Dartmouth College when he visited China for the first time, in 1972. An antiwar activist and a self-described “Mao fan,” he went as part of a group representing the Committee of Concerned Asian Scholars, a radical coalition dedicated to ending the war in Vietnam.

. . .

Not long after arriving in the southern Chinese province of Guangdong, the visiting group was whisked off to meet what was described as a “typical Chinese worker family.” Mr. Mirsky came away impressed. The family seemed prosperous, with a nicely appointed home. Crime, the group was told, was nonexistent.

The next morning, on a stroll around the neighborhood, Dr. Mirsky bumped into the father from that “typical” family. He invited Dr. Mirsky, who was fluent in Mandarin, into his real home, a shabby apartment, and explained that the group had in fact been in a show apartment arranged by the Chinese authorities for “foreign friends.” The man said further that there was no shortage of crime.

“I returned to the hotel, stunned by what I had seen and heard,” Dr. Mirsky recalled in an account of the trip that was published in the 2012 book “My First Trip to China: Scholars, Diplomats and Journalists Reflect on Their First Encounters With China,” edited by Kin-Ming Liu. Afterward, he wrote, he became “suspicious of every venue, every briefing, and every account of how everything should be understood.”

In just 48 hours, Dr. Mirsky went from being a “Mao fan” to a disillusioned skeptic, foreshadowing a similar shift in how left-leaning American intellectuals would come to see the Communist government in China.

“He had a sharp eye for the abuses of totalitarian dictatorship,” said Mr. Garside, the author most recently of “China Coup: The Great Leap to Freedom” (2021). “He was early to denounce the evils of the Mao regime before it became fashionable to do so.”

Dr. Mirsky maintained that skeptical stance even as he made the transition from academia to journalism.

As China correspondent for The Observer, he was at Tiananmen Square in the early morning of June 4, 1989, when the People’s Liberation Army, acting on government orders, launched a bloody crackdown on peaceful protesters. About 3 a.m., he was leaving the scene to file a report with the newspaper when he came upon a group of armed police officers. When they found out he was a journalist, they beat him, fracturing his left arm and knocking out multiple teeth.

Dr. Mirsky managed to dictate his article, which would appear on The Observer’s front page, by phone. The next morning he returned to Tiananmen, where, he said, he saw soldiers shoot parents trying to enter the square to look for children who had not returned home. They also shot doctors and nurses who had come to help the injured, he said.  (. . .)

“Tiananmen Square became a place of horror,” Dr. Mirsky wrote in his article on the day of the crackdown, “where tanks and troops fought with students and workers, where armored personnel carriers burned and blood lay in pools on the stones.”

He was named international reporter of the year at the 1989 British Press Awards ceremony for his Tiananmen coverage.

. . .

Dr. Mirsky was unsparing in his criticism of China’s Communist rulers and the Western leaders whom he believed were overlooking Beijing’s rights abuses to preserve economic ties. Throughout his career he wrote of the Communist Party’s insistence on controlling the narrative of China and, in his view, the deleterious effects this had on Chinese society as a whole.

“For the Chinese, lying creates a universe of uncertainty in which one of the commonest answers to questions is ‘bu qingchu’ — ‘I’m not clear about that’,” he wrote in The Observer in 1993. “There is virtually no aspect of life outside the immediate family or close circle of friends where one can be certain about the truth.”

For the full obituary, see:

Amy Qin. “Jonathan Mirsky, 88, Scholar on China Affairs.” The New York Times (Thursday, September 30, 2021 [sic]): A21.

(Note: ellipses added.)

(Note: the online version of the obituary was updated Sept. 29, 2021 [sic], and has the title “Jonathan Mirsky, Journalist and Historian of China, Dies at 88.”)

Mirsky’s account of the experience that changed him “from being a ‘Mao Fan’ to a disillusioned skeptic” appears in Mirsky’s section of the edited book:

Liu, Kin-ming, ed. My First Trip to China: Scholars, Diplomats, and Journalists Reflect on Their First Encounters with China. Hong Kong: Hong Kong University Press, 2013.

The book by Garside, mentioned above, is:

Garside, Roger. China Coup: The Great Leap to Freedom. Berkeley, CA: University of California Press, 2021.

Communist China Increases Censorship of Negative News and Views of “Struggling Economy”

(p. A16) BEIJING—Several prominent commentaries by economists and journalists in China have vanished from the internet in recent weeks, raising concerns that Beijing is stepping up its censorship efforts as it tries to put a positive spin on a struggling economy.

. . .

. . ., Li Xunlei, an economist at state-owned Zhongtai Securities, warned in a column published on Chinese news outlet Yicai that insufficient household consumption would persist unless China’s leadership took steps to help lower-income families. Li also highlighted a study conducted by Beijing Normal University showing that some 964 million Chinese people, representing roughly 70% of the population, were living on a monthly income of less than 2,000 yuan, equivalent to about $280.

That data point quickly went viral on Weibo before it disappeared from the Chinese microblogging platform’s official list of trending topics. Before long, Li’s column vanished from Yicai’s website too. It has also become inaccessible on Li’s public account on Chinese messaging platform WeChat, where a message read: “The content can’t be viewed due to violation of regulations.”

For the full story, see:

Jonathan Cheng. “Negative Takes on China’s Economy Vanish Online.” The Wall Street Journal (Thursday, February 1, 2024): A16.

(Note: ellipses added.)

(Note: the online version of the story was updated January 31, 2024, and has the title “Negative Takes on China’s Economy Are Disappearing From the Internet.”)

Covid Mandates and Firms Restricting Employee Speech Led Democrat to Invest in Tucker Carlson Media Venture

(p. A18) Five years ago, Omeed Malik was a self-described “run-of-the-mill corporate Democrat,” with a seat on the Council on Foreign Relations, a summer house in the Hamptons, and stints at Bank of America and white-shoe law firm Weil, Gotshal under his belt.

Then Covid happened. Chafing under government mandates he found illogical and corporate limits on speech that felt to him like censorship, he moved from Manhattan to Florida and began hanging out with Republican donors. He discovered a business opportunity in a so-called parallel economy of conservative-friendly companies.

Now, he is one of their financiers. Malik this year launched 1789 Capital, which aims to capitalize on the opportunities that it sees left open by the “wokeness” of more traditional sources of capital.

Its first fund, with a modest $150 million, made its initial investment Monday [Oct. 16, 2023], leading a $15 million seed round with other private investors into Tucker Carlson and Neil Patel’s new media company.

For the full story, see:

Keach Hagey. “1789 Invests in Carlson’s Media Firm.” The Wall Street Journal (Wednesday, Oct. 18, 2023): B1-B2.

(Note: bracketed date added.)

(Note: the online version of the story has the date October 17, 2023, and has the title “Tucker Carlson’s Media Company Secures Investment Led by ‘Anti-Woke’ Firm.”)

“MSNBC’s Business Model . . . Is Flaying Trump 24 Hours a Day”

Maureen Dowd, a leading opinion columnist at The New York Times, is left-wing but sometimes refreshingly blunt, as in some of her comments from right after the Iowa Republican caucuses.

(p. 2) . . . MSNBC refused to carry Trump’s victory speech at all and CNN cut away from the 25-minute remarks after 10 minutes. Fox News, of course, played it all.

Rachel Maddow said her network’s decision was “not out of spite.” It’s not personal — it’s strictly business, as Michael Corleone said. MSNBC’s business model, after all, is flaying Trump 24 hours a day.

For the full commentary, see:

Maureen Dowd. “Can the MAGA Shrew Be Tamed?” The New York Times, SundayOpinion Section (Sunday, January 21, 2024): 2.

(Note: ellipsis added.)

(Note: the online version of the commentary has the date Jan. 20, 2024, and has the same title as the print version.)